This article aims to develop and validate a pathological prognostic model for predicting prognosis in patients with isocitrate dehydrogenase (IDH)-mutant gliomas and reveal the biological underpinning of the prognostic pathological features. Here, IDH3A is linked to central nervous system cancer.